1. Introduction {#sec0005}
===============

It is believed that persistent viral replication together with the resulting liver injury are key risk factors for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).[@bib0205], [@bib0210] Additionally, important viral and host-related factors (genotype, HBV mutants, high HBV viral load, serum hepatitis B surface antigen \[HBsAg\] levels, older age, male gender, excessive alcohol intake and possibly metabolic syndrome) may affect the risk of HCC development.[@bib0215], [@bib0220], [@bib0225] Long-term therapy with nucleos(t)ide analogs (NUC) has improved the overall outcome of chronic hepatitis B (CHB) and resulted in a significant reduction in the need for liver transplantation.[@bib0230] Treatment with the third generation NUCs (entecavir and tenofovir) causes complete suppression of viral replication in more than 95% of the patients, with increased rates of hepatitis B e antigen (HBeAg) seroconversion (in HBeAg positive patients) and improved liver histology including reversal of histological cirrhosis in most cases.[@bib0235], [@bib0240], [@bib0245], [@bib0250], [@bib0255] However, antiviral therapy reduces but does not eliminate the risk of HCC in CHB patients with or without cirrhosis. In fact, evidence of the effect of antiviral therapy on clinical outcomes including HCC related-incidence and mortality is weak, as demonstrated in a recent systematic review and meta-analysis.[@bib0260] Most of the published data about the effect of NUCs on HCC risk are derived from older prospective cohort and case--control studies using lamivudine or interferon. Regarding high-genetic barrier NUCs, most of the available data involve patients treated with entecavir (ETV), with initial reports regarding the effect of ETV being reported by Lampertico et al.[@bib0265] This Italian study demonstrated that CHB patients with compensated cirrhosis and a persistently undetectable serum HBV DNA during 5 years of ETV monotherapy had an annual rate of HCC incidence of 2.5%, which is almost the same risk that had been reported in untreated HBeAg-negative European patients. Retrospective and prospective observational cohort studies that provide HCC data for CHB patients mainly treated with tenofovir disoproxil fumarate (TDF) are lacking. Until recently, the limited data on the risk of HCC following the treatment of CHB patients with TDF were obtained from the roll over study of registration trials in HBeAg-positive (GS-US-174-0103) and HBeAg-negative (GS-US-174-0102) patients.[@bib0270] Buti et al. reported that the incidence of HCC in 152 patients with cirrhosis and 482 with CHB treated with TDF for 5 years was only 3.3% and 1.5%, respectively (annual incidence: 0.7%).[@bib0275] Two recent studies,[@bib0270], [@bib0280] found that TDF reduced HCC incidence compared to the predicted HCC risk using the *Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B* (REACH-B) calculator.

We performed a real-life single-center retrospective observational cohort study of 120 CHB Portuguese patients mainly treated with TDF. Univariate and multivariate analysis (Cox proportional hazards regression) of risk factors associated with HCC development were performed. Accuracy of a HCC-risk score (REACH-B) at baseline was assessed.[@bib0285], [@bib0290]

2. Patients and methods {#sec0010}
=======================

2.1. Study population, clinical and laboratory evaluation {#sec0015}
---------------------------------------------------------

We included consecutive patients with CHB who were treated with tenofovir or entecavir for at least 12 months in Centro Hospitalar Lisboa Ocidental (Hospital Egas Moniz, Hospital Santa Cruz and Hospital São Francisco Xavier) -- a tertiary referral center (catchment population ∼993 000 individuals) -- from January 2006 to February 2014. All patients had a positive HBsAg for at least 6 months. Exclusion criteria were as follows: less than 12 months on NUC therapy (n = 13), pre-existing HCC or HCC diagnosed within the first year of NUC therapy (n = 5), coinfection with hepatitis D virus, hepatitis C virus (n = 6) and/or human immunodeficiency virus (n = 6) -- see [Fig. 1](#fig0005){ref-type="fig"} for flow-chart of study cases selection. Data were collected retrospectively from the medical records, either on paper or electronic charts. HBV DNA was measured by TaqMan (Roche Diagnostics) real-time polymerase chain reaction assay with a linear range of detection from 20 to 1.7 × 10^8^ IU/mL. Alanine aminotransferase (ALT) serum levels were measured biannually, normal range for our laboratory is between 21 and 72 U/L. Patients were retrospectively followed since CHB diagnosis until the end of follow-up or HCC occurrence (duration of follow-up) and since NUC therapy start until the end of follow-up or HCC occurrence (time on NUC therapy). Cirrhosis was defined by ultrasonographic findings (shrunken small liver with a nodular surface), clinical and laboratorial findings compatible with portal hypertension (e.g., ascites, splenomegaly, gastroesophageal varices, thrombocytopenia). Cirrhotic and non-cirrhotic patients with clearly defined risk factors (such as, African patients over 20 year-old, Asian male patients over 40 years-old or female over 50 years-old, patients with family history of HCC) were followed by abdominal ultrasound and serum measurement of alfa-phetoprotein every 6 months, as recommended by guidelines.[@bib0295] Excessive alcohol intake was defined as a daily intake of \>25 g/alcohol. Total virological response was defined as undetectable HBV DNA at 3 or 6 months under antiviral therapy. Partial virological response was defined as a decrease in HBV DNA level of more than 1 log~10~ IU/mL (but still detectable) after 6 months of therapy. Biochemical response was defined as normalization of ALT levels at any time during follow-up. The REACH-B score consists of five parameters: gender, age, ALT level, HBeAg status and HBV DNA level; it ranges from 0 to 17 points.[@bib0285] After exclusion of baseline cirrhotic patients, REACH-B score was calculated at baseline, when patients began treatment. Cutoff values of 8 and 12 points were used to predict risks of HCC. The primary outcome of this study was HCC occurrence as defined by international societies guidelines.[@bib0295] Approval for this study was obtained from our institutional ethics committee -- Comissão de Ética para a Saúde, Centro Hospitalar de Lisboa Ocidental (complying with the Treaty of Helsinki). All study participants, or their legal guardian, provided informed written consent prior to study enrollment.Figure 1Flow-chart of studied cohort population with chronic hepatitis B virus infection treated with nucleos(t)ide analog therapy including the number of patients who developed HCC during the follow-up.

2.2. Statistical analyses {#sec0020}
-------------------------

Statistical analysis was performed using SPSS version 20.0 (SPSS Inc., Chicago, IL). Continuous variables are expressed as mean ± standard deviation or median (interquartile range) as appropriate. Qualitative and quantitative differences between subgroups were analyzed using *χ*^2^ test or Fisher exact test for categorical parameters and Student *t* test or Mann--Whitney test for continuous parameters as appropriate. In order to achieve a comprehensive analysis, subgroup comparisons were performed. Univariate and multivariate analysis by Cox proportional hazards regression model was performed to identify factors associated with HCC. After univariate analysis, variables with a *p* \< 0.05 entered in the multivariate analysis. Effect sizes are expressed as hazard ratios (HRs), adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs). The Kaplan--Meier method was used to estimate the cumulative incidence of HCC at 1, 3 and 5 years on therapy and differences between factors were evaluated by the log-rank test. To assess the performance of the cutoff values for REACH-B score at baseline, we used the receiver operating characteristic (ROC) curve. The sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, positive predictive value and negative predictive value of the different cutoff values for predicting HCC were estimated and reported. All statistical tests were two sided. Statistical significance was taken as *p* \< 0.05.

3. Results {#sec0025}
==========

3.1. Patients' characteristics {#sec0030}
------------------------------

A summary of baseline epidemiological, clinical and laboratorial data of our cohort population is presented in [Table 1](#tbl0005){ref-type="table"}. We identified 120 eligible CHB patients (mean age: 47 ± 14 years-old; 83 male; 80 Caucasian; 32 HBeAg-positive). The median duration of follow-up and time on NUC therapy was 79 months (interquartile: 52--96) and 39 months (interquartile range: 26--54), respectively. A total of 13 patients (11%) had a baseline diagnosis of cirrhosis. Patients with cirrhosis were predominantly male (*p* = 0.060), older (*p* = 0.002) and had a higher prevalence of excessive alcohol intake (*p* = 0.001). Study samples (cirrhotic and non-cirrhotic) were matched regarding duration of follow-up, time on NUC therapy and chosen NUC, previous antiviral therapy, ethnic origin, HBeAg positivity, HBV DNA viral load at baseline, biochemical and virological response. The majority of our population was treated with tenofovir (n = 85; 71%). Seventy-one out of 117 (61%) of the patients were previously treatment-naïve. At the end of follow-up, 9 out of 27 (33%) HBeAg-positive patients had a serological response (HBeAg seroclearance/seroconversion) and one patient demonstrated HBsAg seroclearance/seroconversion.Table 1Subgroup comparison between non-cirrhotic versus cirrhotic CHB patients on antiviral therapy regarding baseline characteristics and HCC prevalence.Table 1Variable -- *n* (%)All patientsNo-cirrhosisCirrhosisAllNo-HCCHCC*p*No-HCCHCC*p*Number of patients120103485Gender -- male83 (69)68 (66)3 (75)1.0007 (88)5 (100)1.000Age -- mean ± SD (y/o)47 ± 1445 ± 1463 ± 8**0.018**57 ± 1065 ± 150.331 • Age ≥ 50 y/o48 (40)34 (33)4 (100)**0.015**6 (75)4 (80)1.000Duration of follow-up (mo) (median;IQR)79 (52;96)79 (52;96)80 (65;94)0.73379 (42;219)79 (45;96)0.754Time on NUC therapy (mo) (median;IQR)39 (26;54)40 (26;55)34 (21;48)0.54630 (25;33)46 (33;49)0.354Tenofovir85 (71)75 (73)2 (50)0.2815 (63)3 (60)1.000Entecavir35 (29)27 (26)2 (50)4 (50)2 (40)  *Ethnic origin* • Caucasian80 (67)68 (66)3 (75)1.0006 (75)3 (60)1.000 • African37 (31)32 (31)1 (25)2 (25)2 (40) • Asian2 (2)2 (2)0 (0)0 (0)0 (0) • Other1 (1)1 (1)0 (0)0 (0)0 (0) Excessive alcohol intake15 (13)8 (8)1 (25)0.2803 (38)3 (60)0.592HBeAg positive (n = 115)32 (29)27 (26)0 (0)0.5703 (38)2 (40)1.000HBV DNA baseline (log~10~IU/mL) (median;IQR)1790 (400;189 521)1578 (337;38 458)15 108 (526;43 593)1.0002551 (167;2 595 229)923 450 (37 025;2 750 000)0.683Cirrhosis at baseline13 (11)N/AN/AN/AN/AN/AN/AREACH-B baseline (median;IQR) (n = 99)[a](#tblfn0005){ref-type="table-fn"}7 (5;9)7 (4;9)10 (8;14)0.109N/AN/AN/A • ≥849 (50)46 (47)3 (75)0.071N/AN/AN/A • ≥1214 (14)12 (12)2 (50)**0.004**N/AN/AN/APrevious antiviral treatment (n = 117)46 (39)42 (41)1 (25)0.6392 (25)1 (20)1.000  *Virologic response (*n *=* *117)* • Total107 (92)92 (89)3 (75)0.3167 (88)5 (100)1.000 • Partial10 (8)8 (8)1 (25)1 (13)0 (0)  *Biochemical response (*n *=* *113)* • Total109 (97)95 (92)3 (75)0.1197 (88)4 (80)1.000HBeAg seroclearance/conversion (n = 27)9 (33)8 (30)0 (0)1 (37)0 (0)HBsAg seroclearance/conversion (n = 95)1 (1)1 (1)0 (0)0 (0)0 (0)[^1][^2]

3.2. Cumulative incidence of HCC {#sec0035}
--------------------------------

At a median treatment duration of 39 months (∼3.3 years), nine patients (7.5%) developed HCC. A slight majority of patients (five out of nine patients; 56%) who developed HCC had underlying cirrhosis at baseline. The calculated cumulative incidence rates of HCC at 1, 3 and 5 years on NUC therapy were 5.1%, 7.3% and 8.8%, respectively, in the entire cohort. The cumulative incidence of HCC was significantly higher in patients with cirrhosis at baseline ([Fig. 2](#fig0010){ref-type="fig"}). In the subgroup of patients without baseline cirrhosis, the cumulative incidence rates of HCC at 1, 3 and 5 years were 3.0%, 3.0% and 4.6%, respectively; in the subgroup of patients with baseline cirrhosis, the cumulative rates were 23.1%, 43% and 43%, respectively.Figure 2Kaplan--Meier analysis of the cumulative incidence of HCC in patients according to baseline cirrhosis status (log-rank \<0.001).

3.3. Factors associated with HCC development {#sec0040}
--------------------------------------------

Patients who developed HCC were older (64 ± 12 vs 46 ± 14; *p* = 0.002), had higher prevalence of excessive alcohol intake (44% vs 10%; *p* = 0.015), higher prevalence of cirrhosis at baseline (56% vs 7%; *p* = 0.001) and higher REACH-B scores at baseline (median 12 points vs 8 points; *p* = 0.002) ([Table 1](#tbl0005){ref-type="table"}). On univariate analysis, age, excessive alcohol intake and cirrhosis at baseline were associated with subsequent development of HCC as seen in [Table 2](#tbl0010){ref-type="table"}. On multivariate analysis, after adjusting for gender and time on NUC therapy, age (aHR: 1.085; 95%CI: 1.021--1.153; *p* = 0.009) and cirrhosis at baseline (aHR: 13.857; 95%CI: 1.105--20.734; *p* = 0.036) were independent predictors for HCC occurrence. Among the non-cirrhotic subgroup ([Table 1](#tbl0005){ref-type="table"}), patients who developed HCC were older (63 ± 8 vs 45 ± 14; *p* = 0.018). On univariate and multivariate analysis ([Table 2](#tbl0010){ref-type="table"}), age and a lack of biochemical response to antiviral therapy were associated with HCC occurrence. In the cirrhotic subgroup, there were no risk factors for HCC occurrence.Table 2Univariate and multivariate analysis of risk factors associated with HCC in CHB patients on antiviral therapy.Table 2VariablesUnivariate analysisMultivariate analysisHR95%CI*p*aHR95%CI*pAll patients*Gender -- male3.3510.418--26.8340.255Age1.1121.049--1.180**\<0.001**1.0851.021--1.153**0.009**Age ≥50 y/o12.5551.569--100.456**0.017**Duration of follow-up0.9950.979--1.0110.540Time on NUC therapy0.9750.935--1.0160.223Tenofovir1.8800.504--7.0090.347Ethnic origin -- Caucasian0.9300.287--3.0160.904Excessive alcohol intake5.8591.572--21.836**0.008**1.9350.420--8.9180.397HBeAg positive0.7170.149--3.4570.679HBV DNA baseline1.0001.000--1.0000.613Cirrhosis at baseline13.8573.541--54.225**\<0.001**4.7871.105--20.734**0.036**Previous antiviral treatment0.4110.085--1.9820.268Virologic response -- total0.7390.092--5.9120.775Biochemical response -- total0.2370.029--1.9410.180  *No-cirrhosis*Gender -- male1.4400.149--13.9260.753Age1.1261.023--1.239**0.015**1.1451.028--1.277**0.014**Duration of follow-up0.9990.977--1.0210.926Time under NUC0.9630.901--1.0290.264Tenofovir2.6860.377--19.1230.324Ethnic origin -- Caucasian0.6770.085--5.3640.712Excessive alcohol intake3.5670.370--34.4140.271HBeAg positive0.0290.000--268.9310.447HBV DNA baseline1.0001.000--1.0000.638REACH-B baseline[a](#tblfn0010){ref-type="table-fn"}1.3140.975--1.7710.073 • ≥82.9680.308--28.5880.346 • ≥126.6550.937--47.2870.058Previous antiviral treatment0.4570.047--4.3930.497Virologic response -- total0.2820.029--2.7230.274Biochemical response -- total0.0860.009--0.836**0.034**0.0080.000--0.686**0.034**  *Cirrhosis*Gender -- male24.2500--7.3 × 10^6^0.620Age1.0480.968--1.1360.249Duration of follow-up0.9900.971--1.0090.281Time under NUC1.0030.952--1.0580.908Tenofovir0.8140.134--4.9520.823Ethnic origin -- Caucasian2.5420.404--15.9970.320Excessive alcohol intake2.3700.391--14.3660.348HBeAg positive1.2870.213--7.7580.783HBV DNA baseline1.0001.000--1.0000.691Previous antiviral treatment0.6400.071--5.7750.691Virologic response -- total24.2500.000--7.3 × 10^6^0.620Biochemical response -- total24.4220--2.6 × 10^7^0.652[^3][^4]

3.4. Performance of REACH-B HCC risk score at baseline {#sec0045}
------------------------------------------------------

[Table 3](#tbl0015){ref-type="table"} and [Fig. 3](#fig0015){ref-type="fig"} show the AUC and diagnostic performance of baseline REACH-B score for HCC prediction among the non-cirrhotic population (n = 107). The AUC was 0.738 (95%CI: 0.521--0.955) for REACH-B score at baseline. At a cutoff value of 8 points, the REACH-B score had 75% sensitivity (three of four HCCs identified) and 51.6% specificity (49 of 95 patients without HCC classified in the low-risk group) to predict HCC during the follow-up period. In the subgroup of non-cirrhotic population previously treatment-naïve (n = 58), the obtained AUC was 0.615 (95%CI: 0.293--0.937).Figure 3The AUC of REACH-B score at baseline to predict HCC.Table 3AUC and diagnostic performance of baseline REACH-B score for HCC in CHB patients on antiviral therapy.Table 3CutoffNo-cirrhosis[a](#tblfn0015){ref-type="table-fn"}No-cirrhosis treatment-naïve8128Value95%CIValue95%CIValue95%CIAUC0.7380.521--0.9550.6150.293--0.937Sensitivity (%)75.020.3--95.950.08.3--91.766.711.6--94.5Specificity (%)51.641.1--61.987.479--93.356.442.3--69.7PPV (%)6.11.4--16.914.32.2--42.87.71.2--25.2NPV (%)98.089.3--99.797.791.7--99.796.983.7--99.5LR+1.550.9--2.83.91.3--12.11.530.65--3.59LR−0.480.1--2.70.570.2--1.50.590.12--2.98No. in high risk491426No. in low risk508532Correct prediction3/42/42/3Correct exclusion49/9583/9531/55[^5][^6]

4. Discussion {#sec0050}
=============

Chronic hepatitis B is a major cause of cirrhosis and hepatocellular carcinoma worldwide, being responsible for 1 million deaths *per* year.[@bib0300] The risk of CHB progression to HCC, *albeit* not being totally eliminated, might be reduced by antiviral therapy,[@bib0305] therefore, the identification and classification of patients who are at increased risk of developing HCC is important. Several HBV risk scores have been published so far.[@bib0310], [@bib0315], [@bib0320], [@bib0325] The REACH-B (*Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B*) score is a simple score, involving non-invasive parameters and has been externally validated.[@bib0285] It is useful to assess the long-term risk of HCC development at 3, 5 and 10 years of follow-up. This risk-prediction score was derived from the community-based Taiwanese REVEAL-HBV study (a cohort of 3584 patients) without cirrhosis and no antiviral treatment. Later, Wong et al. demonstrated that REACH-B score maintained its predictive power in patients on antiviral therapy.[@bib0290]

In the present study, we aimed to assess HCC incidence, risk factors and the performance of REACH-B in predicting HCC development in a Portuguese population (107 patients without cirrhosis) with CHB treated with NUCs (71% with TDF). The estimated prevalence of this infection in the Portuguese population is approximately 1%, which is relatively low,[@bib0330], [@bib0335] however, there is no doubt that HCC incidence in Portugal is on the rise and its associated mortality and costs are high.[@bib0340] In this retrospective cohort study, with a median time on NUC therapy of 39 months (∼3.3 years), 9 out of 120 (7.5%) patients developed HCC, which is similar to the rate reported by Yang et al.[@bib0345] Among patients without cirrhosis, four developed HCC (3.7%), which is similar to the rates reported by Wong et al.[@bib0290] and, recently by Arend et al.[@bib0350] The incidence and clinical presentation of HCC in CHB patients differs significantly by country and ethnic origin. In western countries, HBV related HCC is clearly associated with cirrhosis and excessive alcohol intake,[@bib0355] whereas in Asia and sub-Saharan Africa, HCC can develop in carriers with mild liver fibrosis due to the long standing infection usually acquired at birth.[@bib0360], [@bib0365] Our findings corroborate data from Italy and Greece[@bib0355], [@bib0370] as on multivariate analysis, the independent predictors for HCC development despite NUC therapy were older age (aHR: 1.085; 95%CI: 1.021--1.153; *p* = 0.009) and cirrhosis at baseline (aHR: 4.787; 95%CI: 1.105--20.734; *p* = 0.036).

In the non-cirrhotic CHB patients of our study sample, multivariate analysis found that older age (aHR: 1.145; 95%CI: 1.028--1.277; *p* = 0.014) and a lack of biochemical response to antiviral therapy (aHR: 124.046; 95%CI: 1.457--10559.174; *p* = 0.034) were associated with HCC occurrence, which is supported by a very recent meta-analysis[@bib0375] where age and the proportion of patients with elevated ALT levels predicted the incidence of HCC. Among the cirrhotic population there were no risk factors identified. This is evidence that age might be an important risk factor only in non-cirrhotic patients, whereas, cirrhosis itself is such a strong risk factor that it is seldom influenced by other co-factors (namely age) in the development of HCC. However, we cannot firmly conclude that because, as demonstrated in [Table 1](#tbl0005){ref-type="table"}, our cirrhotic patients were significantly older at baseline than the non-cirrhotic cohort and due to small cirrhotic sample size (n = 13).

Using Kaplan--Meier method ([Fig. 2](#fig0010){ref-type="fig"}) we observed that patients with cirrhosis at baseline had a significantly higher cumulative incidence of HCC (log-rank test \<0.001). Despite not reaching statistical significance, similarly to Wong et al.,[@bib0290] in our study, previous antiviral treatment conferred a modest protective effect (HR: 0.411; 95%CI 0.085--1.982; *p* = 0.268) against HCC occurrence ([Table 2](#tbl0010){ref-type="table"}).

The need for development of HCC risk scores is underlined by the knowledge that NUC therapy cannot completely eliminate the risk of HCC and that the identification of high risk patients might lead intensive HCC surveillance strategies and early detection of HCC and thus to a greater chance of curative treatment with improved survival.[@bib0380] In our study, at a median time on therapy of 3.3 years, the baseline REACH-B AUC obtained for prediction of HCC development (0.738; 95%CI: 0.521--0.955) was lower than the original and validation study of Yang et al.[@bib0285] (AUC for predicting 3-year HCC risk of 0.811; 95%CI: 0.790--831) but similar to that obtained by Wong et al.[@bib0290] (AUC for predicting 5-year HCC risk of 0.71; 95%CI: 0.62--0.81). The cutoff value of 8 points, yielded a sensitivity of 75%, specificity of 51.6%, positive predictive value of 6.1% and negative predictive value of 98%, which is similar to the results of the study by Wong et al.[@bib0290] Also, in parallel with the aforementioned study, the performance of the baseline REACH-B risk score in our subgroup of previously treatment-naïve patients was slightly inferior ([Table 3](#tbl0015){ref-type="table"}). Our data highlights and confirms the major drawbacks of this risk score, which is its high false-positive rate, making it unable to correctly identify low-risk patients, as only 49 out of 95 patients without HCC were classified in the low-risk group. This might be due to the fact that, as in the original study, in our patients, cirrhosis was ruled out by ultrasound only. Another possible limitation of this risk score was described by Kim et al.[@bib0270] Using a population mainly composed of TDF treated patients from the roll-over studies of registration trials, the real incidence of HCC and the incidence predicted based on the REACH-B score was evaluated. The authors found that after 3.3 years there was a progressive divergence between the predicted (by REACH-B score) and the observed number of HCC cases. Most studies addressing HCC occurrence during NUC therapy do not exceed 4--5 years, so it remains to be established if, with longer time on NUC therapy, HCC incidence remains stable. Hence, our data demonstrate that REACH-B score has many limitations especially in Caucasian populations, with AUC of 0.738, using Harrell\'s c-index, it is considered as of modest diagnostic accuracy only. This considerably limits the utility of the score.

In clinical practice, patients at increased baseline HCC risk should continue to undergo regular HCC surveillance according to published guidelines,[@bib0295] however, enhancing this recommendations with the addition of predictive risk scores (REACH-B) may identify additional patients at higher risk of developing HCC (REACH-B score at baseline ≥8 points) and who would thus benefit from HCC surveillance strategies. Accordingly, patients at higher risk for HCC, despite being on antiviral therapy, should undergo HCC surveillance. Notwithstanding, we must note that there is recent evidence demonstrating that a higher HCC detection might not lead to a reduced HCC-related mortality.[@bib0375]

Another possible application for the REACH-B score could be the indication for antiviral treatment initiation, as shown in a recent study,[@bib0385] where the authors demonstrated that the discriminatory performance of the REACH-B score in classifying antiviral treatment eligibility based on the local guideline (APASL 2012) was good/excellent with the exception of older HBeAg-positive patients.

Our study has some limitations, especially data regarding the cirrhotic cohort. It is evident that the cumulative incidence of HCC in cirrhotics was considerably high, exceeding most of previous reports of the South-European area (Italy, Greece, Spain), this is probably due to a small size of the sample. Also, most of the HCC cases in the cirrhotic cohort cumulate in the first months of therapy, suggesting a selection bias. The diagnosis of cirrhosis was based on clinical, laboratorial, radiological and endoscopic features (liver biopsy was not available for the non-cirrhotic population). Hence, patients with histological or early cirrhosis might have been unrecognized. Even with a long follow-up, due to a relatively small and rather heterogeneous cohort sample and the low number of events, our estimation of the accuracy of REACH-B risk score was limited. Another important limitation of our study is related to the fact that REACH-B score was originally derived from an Asian population. Additionally, HBsAg levels quantification, which is a novel marker, known by its high reproducibility and low cost, is currently not available in our institution. In fact, a link between HBsAg levels and HCC was first established by the ERADICATE-B cohort study.[@bib0390] As a consequence, the original REACH-B risk calculator (known to underestimate the risk in patients with very low viral load at baseline) as suffered two major recent upgrades (using Asian cohorts only) in order to maximize its accuracy in predicting HCC occurrence. The most robust and costly REACH-B IIa, that incorporates the original factors plus HBV DNA and HBsAg levels quantification[@bib0395] and the cheapest REACH-B IIb, which incorporates the original factors plus HBsAg levels quantification.[@bib0400] Both upgraded risk calculators need further cost-effectiveness evaluation and external validation.[@bib0225] The diagnosis of cirrhosis based on regular imaging and clinical parameters can be imprecise. Hence, recent developments in non-invasive tests of liver fibrosis may further improve the risk prediction. In fact, in a study performed by Lee and coworkers, the addition of liver stiffness measurement (by transient elastography) to REACH-B improved the diagnostic accuracy to predict liver-related events when compared to REACH-B score alone.[@bib0395] Very recently, another risk score was developed by Papatheodoridis and coworkers in a large multicenter study in 1619 Caucasian European patients under NUC therapy (entecavir and tenofovir), the PAGE-B.[@bib0400] The variables included in this risk score are: age, gender and platelet counts. This risk score appears to be very simple and probably the most suitable HCC risk predictor in Caucasian patients receiving antiviral therapy.

5. Conclusion {#sec0055}
=============

In conclusion, continued HCC surveillance is recommended for CHB patients on antiviral therapy. Age, excessive alcohol intake and cirrhosis remain as the most important risk factors associated with HCC onset in CHB patients on antiviral therapy. REACH-B score has many limitations, especially in Caucasian populations. With an AUC of 0.738 it is considered as of modest diagnostic accuracy and this considerably limits the utility of the score. This is the first study assessing the utility of the REACH-B HCC-risk score in Portugal. Prospective studies using larger samples, longer follow-up periods on antiviral treatment and the use of non-invasive measurement of liver stiffness will be particularly useful in order to clarify the best algorithm for HCC surveillance in CHB patients under nucleos(t)ide analogs therapy.

Ethical disclosures {#sec0060}
===================

Protection of human and animal subjects {#sec0065}
---------------------------------------

The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Confidentiality of data {#sec0070}
-----------------------

The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent {#sec0075}
-------------------------------------

The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

Authorship {#sec0080}
==========

Magalhães-Costa P., Lebre L. and Chagas C. designed the research; Magalhães-Costa P. performed the research; Magalhães-Costa P. analyzed the data and performed the statistical analysis; Magalhães-Costa P. wrote the paper; Lebre L., Peixe P., Santos S. and Chagas C. critically revised the manuscript and approved the final version.

Conflicts of interest {#sec0085}
=====================

The authors have no conflicts of interest to declare.

[^1]: *Abbreviations*: CHB, chronic hepatitis B; NUC, nucleos(t)ide analog therapy; HCC, hepatocellular carcinoma; SD, standard-deviation; y/o, years-old; mo, months; IQR, interquartile range; HBeAg, hepatitis B e antigen; N/A, non-applicable; HBsAg, hepatitis B surface antigen.

[^2]: After excluding patients with cirrhosis at baseline.

[^3]: *Abbreviations*: HCC, hepatocellular carcinoma; CHB, chronic hepatitis B; HR, hazard ratio; aHR, adjusted hazard ratio -- adjusted for gender and time under NUC; CI, confidence interval; y/o, years-old; NUC, nucleos(t)ide analog therapy; HBeAg = Hepatitis B e antigen;

[^4]: After excluding patients with cirrhosis at baseline.

[^5]: *Abbreviations*: AUC, area under the ROC curve; HCC, hepatocellular carcinoma; CHB, chronic hepatitis B; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR−, negative likelihood ratio.

[^6]: Includes treatment-naïve and treatment-experienced patients.
